Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Tests survodutide in adults with liver scarring from fatty liver disease

Tests survodutide, a weekly injection, in adults with MASH cirrhosis.

Plain-language title generated from the registry record
Registry title: LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Key facts

Where
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Jiaxing, Kunming, Liaocheng, Luoyang, Nanchang, Nanjing, Ningbo, Ningxia, Pingxiang, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Xi'an, Zhengzhou, and Zhenjiang, ChinaSee the 50 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a liver disease called MASH (also called NASH) who have compensated cirrhosis and a higher body weight. It tests the weekly injection survodutide against placebo.

Age
18 years or older
Sex
Men and women can join
Disease stage
Compensated MASH (NASH) cirrhosis, meaning cirrhosis without complications of the liver failing; liver fat shown by MRI-PDFF or FibroScan unless a recent liver biopsy shows fatty liver disease
Earlier treatment
Not stated
Biomarker or test result
BMI of 27 kg/m2 or more (25 kg/m2 or more for Asian participants)

Main reasons for not taking part

  • Heavy alcohol use now or in the past 5 years
  • Past or current liver decompensation: bleeding from portal hypertension, ascites or hepatic encephalopathy
  • MELD score above 12 due to liver disease
  • Other chronic liver diseases, or hepatitis B or hepatitis C
  • Liver transplant or being on a transplant list; TIPS or other portal hypertension procedure

Read by machine on 12 November 2026.

Where in China

  • Beijing Ditan Hospital, Capital Medical UniversityBeijing, ChinaContact: Boehringer IngelheimTaking people
  • Beijing Friendship HospitalBeijing, ChinaContact: Boehringer IngelheimTaking people
  • Beijing Tsinghua Changgung HospitalBeijing, ChinaContact: Boehringer IngelheimTaking people
  • Beijing YouAn Hospital,Capital Medical UniversityBeijing, ChinaContact: Boehringer IngelheimTaking people
  • Peking University People's HospitalBeijing, ChinaContact: Boehringer IngelheimTaking people
  • The First Hospital of Jilin UniversityChangchun, ChinaContact: Boehringer IngelheimTaking people
  • Hunan Provincial People's HospitalChangsha, ChinaContact: Boehringer IngelheimTaking people
  • Changzhou Third People's HospitalChangzhou Shi, ChinaContact: Boehringer IngelheimTaking people
  • West China Hospital，Sichuan UniversityChengdu, ChinaContact: Boehringer IngelheimTaking people
  • Chongqing Three Gorges Central HospitalChongqing, ChinaContact: Boehringer IngelheimTaking people
  • The First People's Hospital of FoshanFoshan, ChinaContact: Boehringer IngelheimTaking people
  • The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaContact: Boehringer IngelheimTaking people
  • Guangzhou Eighth People's Hospital, Guangzhou Medical UniversityGuangzhou, ChinaContact: Boehringer IngelheimTaking people
  • Guangzhou First People's HospitalGuangzhou, ChinaContact: Boehringer IngelheimTaking people
  • Nanfang HosptialGuangzhou, ChinaContact: Boehringer IngelheimTaking people
  • Sir Run Run Shaw Hospital Zhejiang University School of MedicineHangzhou, ChinaContact: Boehringer IngelheimTaking people
  • The Affiliated Hospital of Hangzhou Normal UniversityHangzhou, ChinaContact: Boehringer IngelheimTaking people
  • The First Affiliated Hospital, Zhejiang UniversityHangzhou, ChinaContact: Boehringer IngelheimTaking people
  • Zhejiang HospitalHangzhou, ChinaContact: Boehringer IngelheimTaking people
  • The First Hospital Of JiaxingJiaxing, ChinaContact: Boehringer IngelheimTaking people
  • First People's Hospital of Yunnan ProvinceKunming, ChinaContact: Boehringer IngelheimTaking people
  • Liaocheng People's HospitalLiaocheng, ChinaContact: Boehringer IngelheimTaking people
  • The First Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaContact: Boehringer IngelheimTaking people
  • The First Affiliated Hospital of NanChang UniversityNanchang, ChinaContact: Boehringer IngelheimTaking people
  • The Second Affiliated Hospital to Nanchang UniversityNanchang, ChinaContact: Boehringer IngelheimTaking people
  • Nanjing Drum Tower hospitalNanjing, ChinaContact: Boehringer IngelheimTaking people
  • Nanjing Jiangning HospitalNanjing, ChinaContact: Boehringer IngelheimTaking people
  • The Second Hospital of NanjingNanjing, ChinaContact: Boehringer IngelheimTaking people
  • Ningbo Second HospitalNingbo, ChinaContact: Boehringer IngelheimTaking people
  • General Hospital of Ningxia Medical UniversityNingxia, ChinaContact: Boehringer IngelheimTaking people
  • Pingxiang People's HospitalPingxiang, ChinaContact: Boehringer IngelheimTaking people
  • QingDao Municipal HospitalQingdao, ChinaContact: Boehringer IngelheimTaking people
  • Huashan Hospital, Fudan UniversityShanghai, ChinaContact: Boehringer IngelheimTaking people
  • Renji Hospital, Shanghai Jiaotong University School of MedicineShanghai, ChinaContact: Boehringer IngelheimTaking people
  • Renmin Hospital of Wuhan UniversityShanghai, ChinaContact: Boehringer IngelheimTaking people
  • Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Boehringer IngelheimTaking people
  • Shanghai East HospitalShanghai, ChinaContact: Boehringer IngelheimTaking people
  • Shanghai General HospitalShanghai, ChinaContact: Boehringer IngelheimTaking people
  • Shanghai Public Health Clinical CenterShanghai, ChinaContact: Boehringer IngelheimTaking people
  • The Sixth People's Hospital of ShenyangShenyang, ChinaContact: Boehringer IngelheimTaking people
  • The Third People's Hospital of ShenzhenShenzhen, ChinaContact: Boehringer IngelheimTaking people
  • The Fifth People's Hospital of SuzhouSuzhou, ChinaContact: Boehringer IngelheimTaking people
  • Tianjin Second People's HospitalTianjin, ChinaContact: Boehringer IngelheimTaking people
  • Tianjin Third Central HospitalTianjin, ChinaContact: Boehringer IngelheimTaking people
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Boehringer IngelheimTaking people
  • Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Boehringer IngelheimTaking people
  • First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaContact: Boehringer IngelheimTaking people
  • Second Affiliated Hospital of medical college of Xi'an JiaoTong UniversityXi'an, ChinaContact: Boehringer IngelheimTaking people
  • Sixth People's Hospital of ZhengzhouZhengzhou, ChinaContact: Boehringer IngelheimTaking people
  • The Third People's Hospital of ZhenjiangZhenjiang, ChinaContact: Boehringer IngelheimTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Boehringer Ingelheim
Trial code
NCT06632457EU 2024-513741-36-00
Record updated
12 November 2026
Original description
This study is open to adults who are at least 18 years old and have:Read full original descriptionShow less

A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis

This study is open to adults who are at least 18 years old and have:

* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian.

People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function.

Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly.

Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study.

The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.

Inclusion: Male or female adults ≥18 years of age at the time of screening, and at least the legal age of consent in countries where it is >18 years; Body mass index (BMI) ≥27 kg/m2(≥25 kg/m2 for Asian trial participants); Compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis; Magnetic resonance imaging proton density fat fraction (MRI-PDFF) fat fraction ≥5% or FibroScan® with controlled attenuation parameter (CAP) ≥288 dB/m, obtained during the screening period or a historic MRI-PDFF ≤12 weeks prior to randomisation (except for patients with 'cryptogenic cirrhosis' where MRI-PDFF <5% or FibroScan® with CAP <288 dB/m is allowed). This inclusion criterion does not apply for participants with a recent (≤12 months prior to randomisation) liver biopsy showing steatosis/steatohepatitis; Further inclusion criteria apply.

Exclusion: Model of end-stage liver Disease (MELD) score >12 due to liver disease; History or current (i.e. at screening) hepatic decompensation event of any of the following but not limited to:; Portal hypertension-related upper gastrointestinal (GI) bleeding; Ascites; Hepatic encephalopathy (HE) ≥Grade 1 according to the West Haven criteria; History or evidence of other chronic liver diseases, such as primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis or overlap syndrome, Wilson's disease, alpha-1-antitrypsin deficiency, or genetic haemochromatosis; Hepatitis B positive (defined as positive hepatitis B surface antigen (HBsAg)) or history of chronic HBV infection; Hepatitis C positive (defined as positive hepatitis C virus (HCV) antibody and a positive HCV ribonucleic acid (RNA)); Evidence of alcoholic liver disease, or drug-induced liver disease, as defined on the basis of typical exposure and history; History of liver transplantation or listed for liver transplantation; History of transjugular intrahepatic portosystemic shunt (TIPS) or other radiological/surgical procedure for portal hypertension treatment; Any of the following lab test result at screening; Albumin below <3.5 g/dL (<35.0 g/L); International normalised ratio (INR) >1.3 unless due to therapeutic anticoagulants; Total bilirubin (TBL) >1.2x upper limit of normal (ULN) NOTE: Trial participants with Gilbert Syndrome are eligible with a TBL >1.2x ULN if reticulocyte count is within normal limits, haemoglobin is within normal limits unless due to chronic anaemia and unrelated to haemolysis, and direct bilirubin is <20% of TBL; Alkaline phosphatase >1.5x ULN; PLT <100,000/µL (<100 GI/L); Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >5x ULN; Current or history (<5 years) of significant alcohol consumption, defined as an average of >140 g/week in female patients and >210 g/week in male patients, for a period of >3 consecutive months, or an inability to reliably quantify alcohol consumption based upon judgment of the investigator; Further exclusion criteria apply.

ClinicalTrials.gov NCT06632457 · EU CTIS 2024-513741-36-00